ORTHOReBIRTH USA receives FDA clearance for ReBOSSIS: 5 highlights

Written by Megan Wood | January 12, 2018 | Print  |

The FDA cleared ORTHOReBIRTH USA's ReBOSSIS. ORTHOReBIRTH develops orthopedic biologics.

Here are five highlights:

 

1. ReBOSSIS is the sole biosynthetic bone scaffold with electrospun microfiber construction.

 

2. The product is designed for posterolateral spine procedures.

 

3. ReBOSSIS has yielded a 54 percent compression recovery rate.

 

4. Providers have used ReBOSSIS in more than 1,500 procedures.

 

5. ORTHOReBIRTH USA is a wholly owned subsidiary of ORTHOReBIRTH Co.

 

More articles on biologics:
Kleiner Device Labs unveils new spinal bone graft tool: 5 things to know
GI surgical sealant receives CE marking for sale in the EU — 5 insights
1st surgery to treat damaged cartilage with allogeneic stem cells in Japan — 6 key insights

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months